AU3551195A - Chimeric adenovirus for gene delivery - Google Patents

Chimeric adenovirus for gene delivery

Info

Publication number
AU3551195A
AU3551195A AU35511/95A AU3551195A AU3551195A AU 3551195 A AU3551195 A AU 3551195A AU 35511/95 A AU35511/95 A AU 35511/95A AU 3551195 A AU3551195 A AU 3551195A AU 3551195 A AU3551195 A AU 3551195A
Authority
AU
Australia
Prior art keywords
gene delivery
chimeric adenovirus
adenovirus
chimeric
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35511/95A
Inventor
Varavani Dwarki
Tarlochan Nijjar
Srinivas Shankara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somatix Therapy Corp
Original Assignee
Somatix Therapy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somatix Therapy Corp filed Critical Somatix Therapy Corp
Publication of AU3551195A publication Critical patent/AU3551195A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AU35511/95A 1994-09-23 1995-09-12 Chimeric adenovirus for gene delivery Abandoned AU3551195A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31148594A 1994-09-23 1994-09-23
US311485 1994-09-23
PCT/US1995/011537 WO1996009399A2 (en) 1994-09-23 1995-09-12 Chimeric adenovirus for gene delivery

Publications (1)

Publication Number Publication Date
AU3551195A true AU3551195A (en) 1996-04-09

Family

ID=23207088

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35511/95A Abandoned AU3551195A (en) 1994-09-23 1995-09-12 Chimeric adenovirus for gene delivery

Country Status (2)

Country Link
AU (1) AU3551195A (en)
WO (1) WO1996009399A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
AU7665396A (en) * 1995-10-27 1997-05-15 Trustees Of The University Of Pennsylvania, The Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
FR2741358B1 (en) * 1995-11-17 1998-01-02 Centre Nat Rech Scient PRODUCTION OF RETROVIRAL VECTORS VIA DNA VIRUS-BASED VIRAL VECTORS
US20060275781A1 (en) 2004-11-03 2006-12-07 Introgen Therapeutics Inc. Novel method for the protection and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ES2383640T3 (en) * 1996-11-20 2012-06-25 Crucell Holland B.V. Adenovirus compositions that can be obtained by an improved production and purification method
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2002022080A2 (en) * 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CN100361710C (en) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003163A1 (en) * 1991-08-01 1993-02-18 Fondation Nationale De Transfusion Sanguine Expression in non-tumoral human lymphoblastoid lines with an integrative vector

Also Published As

Publication number Publication date
WO1996009399A2 (en) 1996-03-28
WO1996009399A3 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
AU3739697A (en) Gene delivery system
AU5153296A (en) Vectors for gene delivery
AU2946295A (en) Targeted gene delivery system
AU7401698A (en) Decoupled liquid delivery system
AU2319497A (en) Helper-free, totally defective adenovirus for gene therapy
AU3229095A (en) Particle delivery
AU4129396A (en) Diketopiperazine-based delivery systems
AU3703895A (en) Particle delivery
AU2912495A (en) Fluid delivery apparatus
AU4787697A (en) Therapeutic gene
AU3358999A (en) Chimeric adenoviral vectors for targeted gene delivery
AU2816297A (en) Recipient-dosage delivery system
AU1660997A (en) Fluid delivery apparatus
AU8374498A (en) Combination counter-ejector shingle-output delivery system
AU3551195A (en) Chimeric adenovirus for gene delivery
AU5154498A (en) Peptides for gene delivery
AU6659998A (en) Tazarotene-induced gene 3 (tig3)
AUPO692897A0 (en) Dispensing means
AUPO060996A0 (en) Sexing gene
AU7540598A (en) Contrast media
AU6433499A (en) Tnfr related gene 12
AU3036197A (en) Adenovirus vectors for gene therapy
AU8333598A (en) Dispensing system
AU4649396A (en) Gene transduction system
AU5803698A (en) Fluid delivery apparatus